KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $13.7 million.

  • Novavax's Net Cash Flow rose 112.14% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.2 million, marking a year-over-year decrease of 261.47%. This contributed to the annual value of -$30.8 million for FY2024, which is 96.00% up from last year.
  • Novavax's Net Cash Flow amounted to $13.7 million in Q3 2025, which was up 178.63% from -$17.4 million recorded in Q2 2025.
  • Novavax's 5-year Net Cash Flow high stood at $1.4 billion for Q1 2021, and its period low was -$703.5 million during Q1 2023.
  • In the last 3 years, Novavax's Net Cash Flow had a median value of -$84.9 million in 2024 and averaged -$97.2 million.
  • Per our database at Business Quant, Novavax's Net Cash Flow spiked by 1,214.82% in 2021 and then slumped by 1,390.19% in 2023.
  • Quarterly analysis of 5 years shows Novavax's Net Cash Flow stood at -$419.5 million in 2021, then skyrocketed by 112.29% to $51.6 million in 2022, then crashed by 265.77% to -$85.5 million in 2023, then spiked by 61.84% to -$32.6 million in 2024, then surged by 112.14% to $13.7 million in 2025.
  • Its Net Cash Flow stands at $13.7 million for Q3 2025, versus -$17.4 million for Q2 2025 and -$265.9 million for Q1 2025.